Article

Toric posterior chamber phakic lens is safe and effective at one year

According to Alaa El Danasoury and colleagues, Toric ICL (TICL; STAAR Surgical) implantation is safe, effective and predictable in its correction of compound myopic astigmatism.

According to Alaa El Danasoury and colleagues, Toric ICL (TICL; STAAR Surgical) implantation is safe, effective and predictable in its correction of compound myopic astigmatism.

A prospective study conducted at the Magrabi Eye Hospital, Jeddah, Saudi Arabia, enrolled 32 eyes of 21 patients to receive a myopic Toric ICL through a temporal clear corneal incision. All eyes had spherical equivalent (SE) refraction between -5.00 and -15.00 D, spectacle corrected visual acuity (VA) of 20/20 or better, stable manifest refraction for at least one year, endothelial cell counts above 2,200 cell/mm2 and anterior chamber depths of 2.7 mm or more.

Preoperatively the mean SE refraction was -9.32±2.31 D. Twelve months postoperatively this had improved to -0.12±0.45 D. More than 88% of subjects had an uncorrected VA of 20/20 or better and 20/30 or better in all eyes. Two lines or more of spectacle corrected VA was gained by 22% of eyes, while axis misalignment occurred in one eye.

The researchers concluded that implantation of the Toric ICL appears to be effective, predictable and relatively safe for the correction of compound myopic astigmatism, though longer follow-up would be necessary to validate this claim.

A second study conducted by Baha Toygar and co-workers from the Dunya Eye Hospital, Istanbul, Turkey further supported the safety and efficacy of the TICL for the correction of high levels of myopic astigmatism.

A prospective study was conducted that included 27 eyes of 17 subjects whose mean preoperative SE was -10.74±2.17 D, and whose mean preoperative astigmatism was recorded at -2.65±1.03 D. In each patient, the TICL was inserted in the anterior chamber through a temporal corneal incision. After implantation into the sulcus the lens was rotated to the correct axis.

Postoperatively, mean SE was -0.67±1.00 D and mean residual astigmatic error was 0.50±0.45 D. A total of 67% of the eyes were within ±0.50 D of emmetropia and 82% ±1.0 D. Preoperative uncorrected VA improved from 0.02±0.01 to 0.65±0.24 and best corrected VA improved from 0.52±0.23 to 0.78±0.22. In one eye, TICL exchange was performed because of high amounts of vaulting. Furthermore, cataract surgery was performed in one eye after repositioning and then exchanging the TICL.

Toygar concluded that the TICL implantation procedure is both safe and effective.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.